Voyageur Pharmaceuticals Ltd.
VYYRF
$0.13
$0.0218.90%
OTC PK
| 08/31/2025 | 05/31/2025 | 02/28/2025 | 11/30/2024 | 08/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 237.10% | -28.71% | 115.66% | 78.61% | 179.73% |
| Depreciation & Amortization | -33.33% | -33.33% | -33.33% | -25.00% | -25.00% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 241.15% | -28.71% | 115.46% | 78.36% | 178.74% |
| Operating Income | -237.66% | 28.71% | -115.46% | -78.36% | -178.74% |
| Income Before Tax | -262.78% | 6.11% | -133.37% | -61.17% | -167.28% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -262.78% | 6.11% | -133.37% | -61.17% | -167.28% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -262.78% | 6.11% | -133.37% | -61.17% | -167.28% |
| EBIT | -237.66% | 28.71% | -115.46% | -78.36% | -178.74% |
| EBITDA | -238.02% | 28.71% | -115.66% | -78.61% | -179.73% |
| EPS Basic | -200.00% | 20.00% | -105.56% | -50.00% | -171.43% |
| Normalized Basic EPS | -200.00% | 21.05% | -91.67% | -87.50% | -140.00% |
| EPS Diluted | -200.00% | 20.00% | -105.56% | -50.00% | -171.43% |
| Normalized Diluted EPS | -200.00% | 21.05% | -91.67% | -87.50% | -140.00% |
| Average Basic Shares Outstanding | 20.08% | 16.05% | 17.16% | 5.05% | 5.08% |
| Average Diluted Shares Outstanding | 20.08% | 16.05% | 17.16% | 5.05% | 5.08% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |